297 related articles for article (PubMed ID: 18624680)
21. Acute regulation of apical ABC transporters in the gut. Potential influence on drug bioavailability.
Domínguez CJ; Tocchetti GN; Rigalli JP; Mottino AD
Pharmacol Res; 2021 Jan; 163():105251. PubMed ID: 33065282
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the Human Intestinal Drug Transport with Ussing Chamber System Incorporating Freshly Isolated Human Jejunum.
Michiba K; Maeda K; Kurimori K; Enomoto T; Shimomura O; Takeuchi T; Nishiyama H; Oda T; Kusuhara H
Drug Metab Dispos; 2021 Jan; 49(1):84-93. PubMed ID: 33087448
[TBL] [Abstract][Full Text] [Related]
23. Animal models and intestinal drug transport.
Glaeser H; Fromm MF
Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):347-61. PubMed ID: 18433341
[TBL] [Abstract][Full Text] [Related]
24. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
25. Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS.
Fallon JK; Smith PC; Xia CQ; Kim MS
Pharm Res; 2016 Sep; 33(9):2280-8. PubMed ID: 27356525
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of intestinal absorption of amtolmetin guacyl in rats: breast cancer resistant protein as a primary barrier of oral bioavailability.
Rong Z; Xu Y; Zhang C; Xiang D; Li X; Liu D
Life Sci; 2013 Feb; 92(3):245-51. PubMed ID: 23333829
[TBL] [Abstract][Full Text] [Related]
27. The biological and clinical role of drug transporters at the intestinal barrier.
Oostendorp RL; Beijnen JH; Schellens JH
Cancer Treat Rev; 2009 Apr; 35(2):137-47. PubMed ID: 18986769
[TBL] [Abstract][Full Text] [Related]
28. Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Lin X; Skolnik S; Chen X; Wang J
Drug Metab Dispos; 2011 Feb; 39(2):265-74. PubMed ID: 21051535
[TBL] [Abstract][Full Text] [Related]
29. Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption.
Al-Ali AAA; Nielsen RB; Steffansen B; Holm R; Nielsen CU
Int J Pharm; 2019 Jul; 566():410-433. PubMed ID: 31125713
[TBL] [Abstract][Full Text] [Related]
30. Transporter-Mediated Drug-Drug Interactions and Their Significance.
Liu X
Adv Exp Med Biol; 2019; 1141():241-291. PubMed ID: 31571167
[TBL] [Abstract][Full Text] [Related]
31. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.
Cao X; Yu LX; Barbaciru C; Landowski CP; Shin HC; Gibbs S; Miller HA; Amidon GL; Sun D
Mol Pharm; 2005; 2(4):329-40. PubMed ID: 16053336
[TBL] [Abstract][Full Text] [Related]
32. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions.
Marquez B; Van Bambeke F
Curr Drug Targets; 2011 May; 12(5):600-20. PubMed ID: 21039335
[TBL] [Abstract][Full Text] [Related]
33. Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters.
Sasabe H; Shimokawa Y; Shibata M; Hashizume K; Hamasako Y; Ohzone Y; Kashiyama E; Umehara K
Antimicrob Agents Chemother; 2016 Jun; 60(6):3497-508. PubMed ID: 27021329
[TBL] [Abstract][Full Text] [Related]
34. Interaction of Food Additives with Intestinal Efflux Transporters.
Sjöstedt N; Deng F; Rauvala O; Tepponen T; Kidron H
Mol Pharm; 2017 Nov; 14(11):3824-3833. PubMed ID: 28921988
[TBL] [Abstract][Full Text] [Related]
35. Opioids and the Blood-Brain Barrier: A Dynamic Interaction with Consequences on Drug Disposition in Brain.
Chaves C; Remiao F; Cisternino S; Decleves X
Curr Neuropharmacol; 2017 Nov; 15(8):1156-1173. PubMed ID: 28474563
[TBL] [Abstract][Full Text] [Related]
36. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.
Dahan A; Amidon GL
Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230
[TBL] [Abstract][Full Text] [Related]
37. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model.
Cao X; Gibbs ST; Fang L; Miller HA; Landowski CP; Shin HC; Lennernas H; Zhong Y; Amidon GL; Yu LX; Sun D
Pharm Res; 2006 Aug; 23(8):1675-86. PubMed ID: 16841194
[TBL] [Abstract][Full Text] [Related]
38. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
[TBL] [Abstract][Full Text] [Related]
39. Role of intestinal efflux transporters in the intestinal absorption of methotrexate in rats.
Yokooji T; Murakami T; Yumoto R; Nagai J; Takano M
J Pharm Pharmacol; 2007 Sep; 59(9):1263-70. PubMed ID: 17883898
[TBL] [Abstract][Full Text] [Related]
40. Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats.
Juan ME; González-Pons E; Planas JM
J Nutr; 2010 Mar; 140(3):489-95. PubMed ID: 20089784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
